. The Company’s expansive pipeline of clinical development programs remains fully funded into 2025. What this means is that, conservatively, sometime in or before 2025 a CR will be called for if required
This does not mean that we do not need more money, but we will have to wait and see. I trust Joel will not disappoint and his vision now becomes clearer for us down the track. I think there would be many holders here holding on to losses, but this story has some way to go yet, and Nasdaq is a good starting point. We will get the chance to vote and have ample warning of company intentions...........expect a lot more news to drop before we asked to vote on Nasdaq. Results of vote will be interesting indeed.
